Treating CNS sarcoidosis with infliximab and mycophenolate mofetil

Current Neurology and Neuroscience Reports

Volumn 9, Issue 5, 2009, Pages 339-340

  Corbett, James ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SARCOIDOSIS; SHORT SURVEY; TREATMENT DURATION;

EID: 68449100509     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0061-2     Document Type: Short Survey

References (2)

1. Stern BJ, Corbett JJ: Neuro-ophthalmologic manifestations of sarcoidosis. Curr Treat Options Neurol 2007, 9:63-71.
2. Jacob A, Weinshenker BG, Violich I, et al.: Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.